Q1 venture financing round-up: IVD still attracts top private equity dollars; ophthalmology stirs more interest than imaging
This article was originally published in Clinica
Executive Summary
As we moved towards the end of 2010, the investment landscape was looking healthier than it was a year before. Clinica noted that over a third of the private equity financing deals that it covered in the second half of 2010 involved double-digit figures, and half of those deals were between $20-40m (www.clinica.co.uk, 1 February 2011).
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.